113
Participants
Start Date
July 11, 2023
Primary Completion Date
June 23, 2024
Study Completion Date
July 19, 2024
Single dose of PF-07220060 as first Tablet Formulation
A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.
Single dose of PF-07220060 as second Tablet Formulation
A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
Single dose of PF-07220060 as first Tablet Formulation
A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level
Single dose of PF-07220060 as second Tablet Formulation
A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
Single dose of PF-07220060 as a Tablet Formulation
A single dose of PF-07220060 as a tablet formulation administered under fed conditions
Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration
A 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration).
Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration
A 2-treatment fixed sequence of a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal followed by a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)
Single dose of PF-07220060 as third tablet formulation
A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them
New Haven Clinical Research Unit, New Haven
Lead Sponsor
Pfizer
INDUSTRY